The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright

Additional Metadata
Persistent URL dx.doi.org/10.1183/09031936.00099306, hdl.handle.net/1765/30024
Note Free full text at PubMed
Citation
Cazzola, M., MacNee, W., Martinez, F.J., Rabe, K.F., Franciosi, L.G., Barnes, P.J., … Wouters, E.F.M.. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. The European Respiratory Journal, 31(2), 416–468. doi:10.1183/09031936.00099306